Causes of Hypochromic Microcytic Anemia

Introduction

Microcytic anemia is one of the most common findings in clinical hematology. This guide walks through the differential diagnosis systematically — what causes red blood cells to become small and pale, how to tell the causes apart on lab work, and how each is managed today.

The two defining features are simple. Microcytosis means red blood cells are smaller than normal (MCV <80 fL). Hypochromia means they hold less hemoglobin, so they look paler than usual on a blood smear. Both features arise when hemoglobin production fails. A red blood cell that cannot make enough hemoglobin ends up small and pale, and it cannot deliver oxygen efficiently. That oxygen shortage explains the typical symptoms: fatigue, weakness, shortness of breath, and pallor.

Getting the cause right matters. Iron supplements help iron deficiency. They will not help thalassemia, and they can actively harm a patient with sideroblastic anemia who already has iron overload. The rest of this article walks you through each cause, then shows you how to put the lab work together.

Causes of Hypochromic Microcytic Anemia

Iron Deficiency Anemia (IDA)

Iron deficiency anemia is by far the most common cause [3,7]. Without enough iron, the bone marrow cannot make hemoglobin, and the red blood cells it produces are both small and pale.

Why does iron run low? Three mechanisms dominate. First, intake fails to meet demand which is common in pregnancy, in growing children, and in people whose diets rely heavily on plant sources with lower iron bioavailability. Second, absorption fails, as in celiac disease, inflammatory bowel disease, or after bariatric surgery. Third, the body loses iron faster than it can replace it. Heavy menstrual bleeding accounts for most cases in premenopausal women. In men and postmenopausal women, unexplained IDA points strongly toward gastrointestinal blood loss and warrants a search for ulcers, polyps, or malignancy [1].

Symptoms. Fatigue is the cardinal complaint, but iron deficiency causes a range of less obvious signs: brittle nails, hair shedding, restless legs, and pica (cravings for ice, dirt, or starch). Children may have learning difficulties or developmental delay.

Diagnosis. A CBC shows low hemoglobin, low MCV, and low MCH. Iron studies confirm: serum iron is low, ferritin is low, transferrin (and TIBC) is high, and transferrin saturation is low. Current AGA guidance defines iron deficiency in an anemic adult as a ferritin under 45 ng/mL, which gives 85% sensitivity and 92% specificity [1]. The British Society of Gastroenterology similarly endorses ferritin as the primary test [2].

Investigating the cause is part of the diagnosis. AGA guidelines recommend bidirectional endoscopy (upper and lower) for men and postmenopausal women with IDA, plus screening for celiac disease (found in 3–5% of IDA cases) and Helicobacter pylori infection [1].

Treatment. Oral iron (ferrous sulfate, fumarate, or gluconate) is first-line for most patients. Taking it on an empty stomach with vitamin C improves absorption, but causes more gastrointestinal upset. In fact, alternate-day dosing is now increasingly recommended as the clinical gold standard over daily dosing. Taking oral iron every other day prevents the hepcidin spike that blocks subsequent absorption, thereby maximizing iron uptake while significantly reducing gastrointestinal side effects [11]. Intravenous iron formulations (ferric carboxymaltose, ferric derisomaltose, iron sucrose) are preferred when oral iron fails, is not tolerated, or absorption is impaired which are common scenarios in IBD, CKD, heart failure, and the postpartum period [2,3]. Clinicians must be aware, however, that certain intravenous formulations specifically ferric carboxymaltose (FCM) carry a significant risk of inducing severe hypophosphatemia by elevating Fibroblast Growth Factor 23 (FGF23) levels. Phosphate levels should be monitored in patients receiving high or repeated doses of FCM [12]. A meaningful hemoglobin rise within two weeks of starting iron strongly supports the diagnosis [2]. Always treat the underlying source of bleeding.

Anemia of Chronic Disease (ACD)

Anemia of chronic disease, also called anemia of inflammation, is the second most common type of anemia overall and a frequent cause of confusion in the microcytic anemia workup [4].

Pathophysiology in one line. Chronic inflammation drives hepcidin up. Hepcidin blocks iron from leaving macrophages and being absorbed from the gut, so the bone marrow effectively starves even though the body's iron stores are full [4].

Why is it sometimes microcytic? ACD is classically normocytic and normochromic. However, when inflammation is prolonged as in poorly controlled rheumatoid arthritis or chronic infection, the sustained iron sequestration eventually produces functional iron deficiency in erythroid precursors, and the cells become microcytic and hypochromic. This is why ACD belongs in the microcytic anemia differential.

Common triggers. Autoimmune disease (rheumatoid arthritis, SLE, IBD), chronic infections (tuberculosis, osteomyelitis, HIV), cancers, and chronic kidney disease.

Lab findings. Low serum iron, low or normal transferrin/TIBC (the opposite of IDA), and normal or elevated ferritin. CRP and ESR are typically up.

The hard case: IDA on top of ACD. A patient with rheumatoid arthritis and a bleeding peptic ulcer can have both. Standard iron studies often cannot tell them apart. Two advanced tests help:

• Soluble transferrin receptor (sTfR): elevated in true iron deficiency, normal in pure ACD.
• sTfR / log ferritin index: values >2 suggest IDA or mixed IDA+ACD, values <1 suggest pure ACD.

Treatment. Treat the underlying condition. Erythropoiesis-stimulating agents (ESAs) have historically helped selected patients, particularly those with CKD. Recently, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, such as daprodustat (FDA-approved in 2023), have emerged as a major alternative to injectable ESAs. These agents stimulate endogenous erythropoietin and lower hepcidin levels, mobilizing sequestered iron from macrophages [13]. Transfusions are reserved for severe symptomatic anemia.

Thalassemia

Thalassemia is a group of inherited disorders affecting the alpha or beta globin chains of hemoglobin. The severity spans a spectrum from asymptomatic carriers to lifelong transfusion-dependent disease.

The genetics. Beta-thalassemia results from mutations in the HBB gene on chromosome 11. Alpha-thalassemia results from deletions or mutations affecting one or more of the four alpha-globin genes on chromosome 16. The number and type of affected genes determines severity.

Thalassemia trait (one defective gene set) usually causes mild microcytosis with little or no anemia. Carriers are typically asymptomatic but pass the gene to children. Thalassemia major (transfusion-dependent thalassemia, TDT) presents in early childhood with severe anemia, failure to thrive, jaundice, skeletal deformities, and an enlarged spleen and liver. Thalassemia intermedia sits between these.

Diagnosis. A CBC shows microcytic, hypochromic indices but with an important clue: the RBC count is typically normal or high in thalassemia trait, unlike IDA. The Mentzer Index (MCV ÷ RBC count) helps with a number under 13 suggests thalassemia, over 13 suggests iron deficiency. Confirmation comes from hemoglobin electrophoresis or HPLC, which shows elevated HbA2 in beta-thalassemia trait. Genetic testing can pin down specific mutations.

Treatment. Trait requires no treatment but warrants genetic counseling, especially for couples planning children. For thalassemia major, treatment has changed substantially in the last decade:

• Regular transfusions maintain hemoglobin and suppress ineffective erythropoiesis.
• Iron chelation therapy is essential because every unit of blood adds about 200–250 mg of iron, and the body has no way to excrete excess iron. Deferasirox, deferiprone, and deferoxamine are the standard agents.
• Luspatercept (Reblozyl) was FDA-approved in 2019 for adults with TDT who need regular transfusions. It works as a ligand trap for TGF-β superfamily proteins, promoting late-stage red cell maturation. In the BELIEVE trial, 21.4% of treated patients achieved a ≥33% reduction in transfusion burden, versus 4.5% on placebo [5].
• Mitapivat, an oral pyruvate kinase (PK) activator, represents a significant new therapeutic frontier. Following successful clinical trials, it has demonstrated the ability to improve hemoglobin levels and reduce transfusion burdens across both alpha- and beta-thalassemia by enhancing red blood cell energy metabolism and reducing hemolysis [14].
• Allogeneic hematopoietic stem cell transplantation remains the established curative option when a matched donor is available.
• Gene therapy. Casgevy (exagamglogene autotemcel, exa-cel), approved by the FDA in January 2024 for patients aged 12 and older with TDT, uses CRISPR-Cas9 to edit the patient's own stem cells, reactivating fetal hemoglobin production. In trials, the majority of treated patients became transfusion-independent [6]. Lyfgenia (betibeglogene autotemcel) is another gene therapy option approved earlier. Access remains limited by cost and the need for specialized treatment centers.

Sideroblastic Anemia

Sideroblastic anemia is a group of disorders in which iron cannot be incorporated into hemoglobin even though stores are adequate or high. The bone marrow accumulates ring sideroblasts which are erythroblasts with iron-loaded mitochondria forming a ring around the nucleus. The result is microcytic, hypochromic anemia alongside iron overload, an unusual combination.

Causes.

• Inherited: Most commonly X-linked sideroblastic anemia, caused by ALAS2 mutations. Some forms respond to vitamin B6 (pyridoxine).
• Acquired: Myelodysplastic syndrome with ring sideroblasts (MDS-RS), alcohol abuse, certain medications (isoniazid, chloramphenicol, linezolid), copper deficiency, and lead poisoning.

Diagnosis. CBC shows microcytic, hypochromic anemia. Iron studies show high serum iron and ferritin — the opposite of IDA. Bone marrow aspiration with Prussian blue staining is the gold standard, revealing ring sideroblasts.

Treatment. Address the cause: stop offending drugs, treat alcohol use disorder, give vitamin B6 for responsive cases. Iron chelation may be needed for iron overload. Luspatercept is approved for MDS-RS. Stem cell transplantation is reserved for severe inherited or MDS-associated disease.

IRIDA (Iron-Refractory IDA with Ring Sideroblasts)

IRIDA is a rare genetic disorder caused by mutations in TMPRSS6, which encodes the protein matriptase-2. Matriptase-2 normally suppresses hepcidin. When it does not work, hepcidin levels stay inappropriately high, blocking iron absorption from the gut. Patients have microcytic, hypochromic anemia with low transferrin saturation but a normal or only mildly low ferritin [8].

The clinical hallmark is that oral iron does not work. These patients are refractory by definition. They need intravenous iron, often repeatedly.

Lead Poisoning

Lead disrupts heme synthesis at multiple enzymatic steps, particularly ALA dehydratase and ferrochelatase. The result is reduced hemoglobin production plus a shortened red cell lifespan, producing microcytic anemia.

Exposure sources. Lead paint in older homes, contaminated soil and water, occupational exposure (battery manufacturing, smelting, construction), and some imported cosmetics, traditional remedies, and pottery glazes.

Clinical features. In children: irritability, learning difficulties, abdominal pain, developmental delay. In adults: headaches, peripheral neuropathy, hypertension, abdominal pain, and reproductive effects.

Diagnosis. Blood lead level is the definitive test. The CDC's blood lead reference value is now 3.5 µg/dL (updated 2021) and any child above this threshold warrants public health intervention. Basophilic stippling on the peripheral smear is a classic but non-specific clue.

Treatment. Remove the lead source. Chelation therapy (succimer, EDTA, or dimercaprol for severe cases) is reserved for significantly elevated levels. Supportive care for anemia and developmental support are essential [10].

Diagnosing Hypochromic Microcytic Anemia

Working up a microcytic anemia is a logical sequence, not a memorized list.

Step 1: Take a focused history

Ask about diet, menstrual losses, GI symptoms, family history of anemia or thalassemia, ethnicity (higher thalassemia prevalence in Mediterranean, Middle Eastern, South Asian, and Southeast Asian populations), medications (NSAIDs, aspirin), and possible lead exposure.

Step 2: Read the CBC carefully

Beyond MCV and MCH, look at:

• RBC count. Low in IDA, normal or high in thalassemia trait.
• RDW. Elevated in IDA, usually normal in thalassemia trait.
• Mentzer Index (MCV ÷ RBC). >13 → IDA, <13 → thalassemia trait.
• Reticulocyte count. Low in production problems, high if the body is compensating.

Step 3: Order iron studies

Serum iron, ferritin, TIBC (or transferrin), and transferrin saturation. This single panel separates most causes:

Step 4: When iron studies are ambiguous, escalate

In patients with co-existing inflammation, kidney disease, or partial responses to therapy, conventional iron studies often mislead. Three biomarkers help [3,4]:

• Soluble Transferrin Receptor (sTfR). Elevated in true iron deficiency, normal in ACD. Unlike ferritin, it is not affected by inflammation.
• sTfR / log ferritin index. Values >2 suggest IDA (with or without ACD); values <1 suggest pure ACD.
• Reticulocyte Hemoglobin Equivalent (Ret-He or CHr). Reflects iron supply over the last 1–2 days, not the last 1–2 months. A value below 29 pg signals iron-deficient erythropoiesis happening right now, useful for monitoring response to IV iron.
• Hepcidin. Suppressed in IDA, elevated in ACD, inappropriately high in IRIDA. Useful for understanding the pathophysiology, though still mostly a research tool.
• Bone marrow aspirate with Prussian blue staining remains the gold standard when non-invasive tests fail. It shows absent iron stores in IDA, trapped iron in macrophages in ACD, and ring sideroblasts in sideroblastic anemia.

Why an Accurate Diagnosis Matters

Treatment is wrong if the diagnosis is wrong. Iron supplements treat iron deficiency. They do nothing for thalassemia, and they can worsen sideroblastic anemia by adding to existing iron overload. An accurate diagnosis also flags consequential downstream issues: unexplained IDA in a 65-year-old man may be the first sign of colon cancer; mild microcytosis in a young adult planning a family may signal thalassemia trait that warrants genetic counseling.

Frequently Asked Questions (FAQs)

What MCV value defines microcytic anemia?

Microcytic anemia is defined by a Mean Corpuscular Volume below 80 femtoliters (fL) in adults, measured on a Complete Blood Count. The lower limit varies slightly in children. Microcytosis is a finding, not a diagnosis, so it always prompts further investigation. The most common causes are iron deficiency, thalassemia, and anemia of chronic disease.

How do you tell iron deficiency anemia apart from thalassemia trait on a blood test?

Three CBC features help. In iron deficiency anemia, the red blood cell count is low and the Red Cell Distribution Width (RDW) is elevated. In thalassemia trait, the RBC count is normal or high and the RDW is usually normal. The Mentzer Index (MCV ÷ RBC count) is a quick screening tool: a value greater than 13 suggests iron deficiency, less than 13 suggests thalassemia trait. Confirmation requires a low ferritin for iron deficiency, or hemoglobin electrophoresis showing elevated HbA2 for beta-thalassemia trait.

What ferritin level confirms iron deficiency?

In an adult with anemia, a serum ferritin below 45 ng/mL is the current AGA-recommended threshold for diagnosing iron deficiency, giving 85% sensitivity and 92% specificity [1]. The older WHO cutoff of <15 ng/mL is highly specific but misses many cases. Ferritin is an acute-phase reactant and can be falsely normal or elevated in inflammation, infection, malignancy, or chronic kidney disease. In such inflammatory states, functional iron deficiency is clinically recognized at much higher thresholds, typically a serum ferritin <100 ng/mL, or a ferritin <300 ng/mL if the transferrin saturation (TSAT) is <20% [15]. In these complex clinical settings, relying on these updated thresholds, alongside tests like sTfR or Ret-He, is crucial for timely diagnosis.

Why do thalassemia patients need iron chelation if their problem is reduced hemoglobin?

The anemia in severe thalassemia is not from iron deficiency. The body's defective hemoglobin production drives increased gut iron absorption, and repeated blood transfusions add even more iron. The human body has no efficient way to excrete excess iron, so it accumulates in the heart, liver, and endocrine glands, causing organ damage. Chelation drugs like deferasirox, deferiprone, and deferoxamine bind iron and remove it through urine or stool.

Can iron deficiency anemia be a sign of cancer?

Yes, particularly in men and postmenopausal women. Unexplained iron deficiency anemia in these groups often points to chronic gastrointestinal blood loss, including from colon cancer. AGA guidelines recommend bidirectional endoscopy (upper and lower) for these patients, along with screening for celiac disease and H. pylori infection [1]. In premenopausal women, heavy menstrual bleeding is the more common cause, but malignancy is still considered when standard treatment fails.

What new treatments are available for severe beta-thalassemia?

Two major advances have changed the landscape. Luspatercept (Reblozyl), FDA-approved in 2019, reduces transfusion needs by promoting late-stage red cell maturation. About 21% of treated patients in the BELIEVE trial achieved a one-third reduction in transfusion burden [5]. Casgevy (exa-cel), approved in January 2024 for patients aged 12 and older, is a CRISPR-Cas9 gene therapy that edits the patient's own stem cells to boost fetal hemoglobin, offering a one-time potential cure for transfusion-dependent disease [6]. Allogeneic stem cell transplantation remains the established curative option when a matched donor is available.

Glossary of Related Medical Terms

• Anisocytosis: variation in red blood cell size, measured by RDW. Elevated in iron deficiency, normal in thalassemia trait.
• Erythropoiesis: red blood cell production in the bone marrow, driven by erythropoietin from the kidneys.
• Ferritin: the body's main iron storage protein. Serum ferritin reflects iron stores but rises with inflammation.
• Hepcidin: liver hormone that regulates iron. High hepcidin traps iron in storage and blocks gut absorption.
• Mean Corpuscular Hemoglobin (MCH): average hemoglobin per red blood cell. <27 pg suggests hypochromia.
• Mean Corpuscular Volume (MCV): average red blood cell size. <80 fL defines microcytosis.
• Mentzer Index: MCV ÷ RBC count. >13 suggests iron deficiency, <13 suggests thalassemia trait.
• Reticulocyte: an immature red blood cell. Ret-He measures hemoglobin in reticulocytes, giving a real-time snapshot of iron availability.
• Ring sideroblast: erythroblast with iron-laden mitochondria forming a ring around the nucleus. Diagnostic for sideroblastic anemia on Prussian blue stain.
• Total Iron-Binding Capacity (TIBC): indirect measure of transferrin. Rises in iron deficiency, falls in chronic disease.
• Transferrin saturation (TSAT): percent of transferrin carrying iron. Less than 16% strongly suggests iron deficiency.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Ko, C. W., Siddique, S. M., Patel, A., Harris, A., Sultan, S., Altayar, O., & Falck-Ytter, Y. (2020). AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology, 159(3), 1085–1094. https://doi.org/10.1053/j.gastro.2020.06.046
2. Snook, J., Bhala, N., Beales, I. L. P., Cannings, D., Kightley, C., Logan, R. P., Pritchard, D. M., Sidhu, R., Surgenor, S., Thomas, W., Verma, A. M., & Goddard, A. F. (2021). British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut, 70(11), 2030–2051. https://doi.org/10.1136/gutjnl-2021-325210
3. Camaschella C. (2019). Iron deficiency. Blood, 133(1), 30–39. https://doi.org/10.1182/blood-2018-05-815944
4. Weiss, G., Ganz, T., & Goodnough, L. T. (2019). Anemia of inflammation. Blood, 133(1), 40–50. https://doi.org/10.1182/blood-2018-06-856500
5. Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H. K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., Chew, L. P., … BELIEVE Investigators (2020). A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. The New England journal of medicine, 382(13), 1219–1231. https://doi.org/10.1056/NEJMoa1910182
6. Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., Mapara, M., Liem, R. I., Cappellini, M. D., Algeri, M., Kattamis, A., Sheth, S., Grupp, S., Handgretinger, R., Kohli, P., Shi, D., … CLIMB THAL-111 Study Group (2024). Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. The New England journal of medicine, 390(18), 1663–1676. https://doi.org/10.1056/NEJMoa2309673
7. Camaschella C. (2015). Iron-deficiency anemia. The New England journal of medicine, 372(19), 1832–1843. https://doi.org/10.1056/NEJMra1401038
8. Heeney, M. M., & Finberg, K. E. (2014). Iron-refractory iron deficiency anemia (IRIDA). Hematology/oncology clinics of North America, 28(4), 637–v. https://doi.org/10.1016/j.hoc.2014.04.009
9. Bottomley, S. S., & Fleming, M. D. (2014). Sideroblastic anemia: diagnosis and management. Hematology/oncology clinics of North America, 28(4), 653–v. https://doi.org/10.1016/j.hoc.2014.04.008
10. Wani, A. L., Ara, A., & Usmani, J. A. (2015). Lead toxicity: a review. Interdisciplinary toxicology, 8(2), 55–64. https://doi.org/10.1515/intox-2015-0009
11. Stoffel, N. U., Cercamondi, C. I., Brittenham, G., Zeder, C., Geurts-Moespot, A. J., Swinkels, D. W., Moretti, D., & Zimmermann, M. B. (2017). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. The Lancet. Haematology, 4(11), e524–e533. https://doi.org/10.1016/S2352-3026(17)30182-5
12. Wolf, M., Chertow, G. M., Macdougall, I. C., Kaper, R., Krop, J., & Strauss, W. (2018). Randomized trial of intravenous iron-induced hypophosphatemia. JCI insight, 3(23), e124486. https://doi.org/10.1172/jci.insight.124486
13. Singh, A. K., Carroll, K., Perkovic, V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Więcek, A., Blackorby, A., Cizman, B., Cobitz, A. R., Davies, R., Dole, J., Kler, L., Meadowcroft, A. M., … ASCEND-D Study Group (2021). Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. The New England journal of medicine, 385(25), 2325–2335. https://doi.org/10.1056/NEJMoa2113379
14. Kuo, K. H. M., Layton, D. M., Lal, A., Al-Samkari, H., Bhatia, J., Kosinski, P. A., Tong, B., Lynch, M., Uhlig, K., & Vichinsky, E. P. (2022). Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. Lancet (London, England), 400(10351), 493–501. https://doi.org/10.1016/S0140-6736(22)01337-X
15. Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., … ESC Scientific Document Group (2022). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure, 24(1), 4–131. https://doi.org/10.1002/ejhf.2333